Novo's antibiotic fund participates in financing round of infectious diseases firm
![Photo: Novo Holdings / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13742125.ece/ALTERNATES/schema-16_9/doc7jqxnx6vli8qh9hr7pz.jpg)
British biotech firm Centauri has secured USD 32m to advance its platform for antimicrobial resistance (AMR) research and development, which can identify and develop new antibacterial candidates designed to treat infectious diseases, Novo Holdings announces in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.